6.16
Schlusskurs vom Vortag:
$5.95
Offen:
$6.08
24-Stunden-Volumen:
5.07M
Relative Volume:
1.06
Marktkapitalisierung:
$1.19B
Einnahmen:
$71.80M
Nettoeinkommen (Verlust:
$-183.59M
KGV:
-5.8427
EPS:
-1.0543
Netto-Cashflow:
$-186.52M
1W Leistung:
+6.02%
1M Leistung:
-3.75%
6M Leistung:
-60.36%
1J Leistung:
-10.72%
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd
|
6.16 | 1.19B | 71.80M | -183.59M | -186.52M | -1.0543 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | BofA Securities | Buy |
| 2025-12-12 | Bestätigt | Wedbush | Outperform |
| 2025-12-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
Price-Driven Insight from (WVE) for Rule-Based Strategy - Stock Traders Daily
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
The Bull Case For Wave Life Sciences (WVE) Could Change Following A Zacks Earnings-Estimate Upgrade - simplywall.st
WAVE Life Sciences Ltd (WVE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
WAVE Life Sciences Ltd (WVE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WAVE Life Sciences Ltd (WVE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
WAVE Life Sciences Ltd (WVE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
WAVE Life Sciences Ltd (WVE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
WAVE Life Sciences Ltd (WVE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Wave Life Sciences (WVE) Stock Could Be 73% Undervalued After WVE 006 Data - simplywall.st
Wave Life Sciences (WVE) Upgraded to Buy: Here's Why - Yahoo Finance
WAVE Life Sciences Ltd (WVE) Institutional Confidence - TradingKey
Wave Life Sciences Ltd. (WVE) stock price, news, quote and history - Yahoo Finance UK
Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now? - Insider Monkey
What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
WVE News | WAVE LIFE SCIENCES LTD (NASDAQ:WVE) - ChartMill
Failed Obesity Trial And Investor Exit Might Change The Case For Investing In Wave Life Sciences (WVE) - Sahm
Inside Wells Fargo’s Take on Wave Life Sciences Ltd (WVE) Stock - Insider Monkey
H.C. Wainwright Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Billionaire Lee Ainslie’s 5 Stocks with Huge Upside Potential - Insider Monkey
WVE Stock Price, Quote & Chart - ChartMill
(WVE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Transcript : Wave Life Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08 - marketscreener.com
WVE: WVE-007 advances to phase II-A for obesity, with RNA editing programs nearing key milestones - TradingView
Wave Life Sciences (WVE) Valuation After Obesity Drug Setback And Institutional Investor Exit - simplywall.st
Wave Life Sciences Faces Setback As WVE-007 Fails And Investor Exits - simplywall.st
WAVE LIFE SCIENCES LTD (WVE) Stock Chart - ChartMill
Wave Life Sciences Hits Day Low at $5.65 Amid Price Pressure - MarketsMojo
AI’s rising power demand brings wave energy to NVIDIA GTC stage - Stock Titan
Wave Life Sciences to Present at Upcoming Investor Conferences - The Manila Times
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter - AOL.com
Is RNA Editor WVE-006’s MZ-Like AAT Restoration Altering The Investment Case For Wave Life Sciences (WVE)? - simplywall.st
Wave Life Science prices upsized $350M stock ofeering - MSN
Wells Fargo Maintains Wave Life Sciences (WVE) Overweight Recommendation - MSN
(WVE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
EDGAR Filing Documents for 0001193125-25-044876 - SEC.gov
Wedbush Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Investigation launched into Wave Life Sciences over possible securities law violations after stock drop - Pluang
Wave Life Sciences Ltd. Shareholders Are Encouraged to - GlobeNewswire
Wave Life Sciences(WVE) Stock Options Chain | Quotes & News - Moomoo
Should WVE-006’s RNA-Editing AAT Data Shift the Risk-Reward Calculus for Wave Life Sciences (WVE) Investors? - Yahoo Finance
Wave Life Sciences (WVE) Valuation Check After Sharp Share Price Weakness - simplywall.st
WAVE Life Sciences Analyst Ratings and Price Targets | NASDAQ:WVE - Benzinga
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences (WVE) Is Down 11.4% After Positive WVE-006 AATD Data and Accelerated Path Update - simplywall.st
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data - Seeking Alpha
WVE Maintained by Wells Fargo -- Price Target Raised to $14.00 - GuruFocus
Wave Life Sciences Is Maintained at Overweight by Wells Fargo - Moomoo
CCORF Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $43 - Moomoo
WVE: Advancing siRNA and RNA editing therapies with strong clinical data and regulatory momentum - TradingView
Wells Fargo raises Wave Life Sciences price target on AATD data - Investing.com Australia
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):